In this proposal, we build on our previous work using Positron Emission Tomography (PET) to contribute to the management of sarcoma patients. Our proposed studies in sarcoma patients also serve as a model for PET applications in other types of cancer. Using [F-18] fluorodeoxyglucose (FDG) and PET/CT, we will perform prospective imaging studies on patients to determine their tumor metabolism for identification of treatment response, and the ability of these measures to predict outcome. This work will continue our evaluation of the ability of FDG PET derived tumor measures to assess and predict time to local tumor recurrence, metastasis and death using rigorous statistical methods based on standard epidemiology concepts. Imaging data as surrogate endpoints for clinical outcome will be tested with hypothesis driven studies for validation with clinical outcomes data. The first specific aim will address characterization of tumor response to neoadjuvant chemotherapy in patients with soft tissue sarcomas. This image derived response measure will be validated by correlation with patient outcome to determine the ability of FDG PET/CT imaging to be used as a surrogate endpoint for treatment effectiveness in this group of patients. In the second specific aim, FDG PET imaging will be used in a similar manner to characterize treatment response in the pediatric and young adult population of patients with osteosarcoma and Ewings Sarcoma Family of Tumors (ESFT) which includes peripheral neuroectodermal tumors. As in the previous aim, we will evaluate the ability of the FDG PET image derived measure of tumor response to predict patient outcome after neoadjuvant chemotherapy. In a third specific aim, we will continue our previous work in quantitating measures of tumor heterogeneity in FDG metabolism using our statistical image analysis methods for complex tumor FDG uptake distribution. These data will be analyzed for their ability to predict tumor response, and patient overall survival. This new image analysis algorithm will be applied to generate a semi- quantitative and spatial assessment of the tumor surface with statistical methods. The focus of these studies are to exploit the quantitative data and high level of spatial sensitivity in FDG PET images to characterize tumor metabolism and to continue to develop image analysis methods that provide relevant data and insights on tumor biologic aggressiveness.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA065537-16
Application #
8097581
Study Section
Special Emphasis Panel (ZRG1-SBIB-S (02))
Program Officer
Menkens, Anne E
Project Start
1995-08-14
Project End
2013-06-30
Budget Start
2011-08-31
Budget End
2013-06-30
Support Year
16
Fiscal Year
2011
Total Cost
$344,360
Indirect Cost
Name
University of Washington
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Eary, Janet F; Conrad, Ernest U; O'Sullivan, Janet et al. (2014) Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg Am 96:152-8
Yan, Jinchun; Jones, Robin L; Lewis, David H et al. (2013) Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis. Clin Nucl Med 38:453-5
Hawe, David; Hernández Fernández, Francisco R; O'Suilleabháin, Liam et al. (2012) Kinetic Analysis of Dynamic Positron Emission Tomography Data using Open-Source Image Processing and Statistical Inference Tools. Wiley Interdiscip Rev Comput Stat 4:316-322
Pollack, Seth M; Li, Yonqing; Blaisdell, Megan J et al. (2012) NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7:e32165
Pollack, Seth M; Jungbluth, Achim A; Hoch, Benjamin L et al. (2012) NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118:4564-70
O'Sullivan, F; Wolsztynski, E; O'Sullivan, J et al. (2011) A statistical modeling approach to the analysis of spatial patterns of FDG-PET uptake in human sarcoma. IEEE Trans Med Imaging 30:2059-71
Eary, Janet F; Hawkins, Douglas S; Rodler, Eve T et al. (2011) (18)F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 1:47-53
Eary, Janet F; Link, Jeanne M; Muzi, Mark et al. (2011) Multiagent PET for risk characterization in sarcoma. J Nucl Med 52:541-6
Hawkins, Douglas S; Conrad 3rd, Ernest U; Butrynski, James E et al. (2009) [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer 115:3519-25

Showing the most recent 10 out of 29 publications